Quidel to Host 2013 Analyst and Investor Day in Boston

Mon Feb 25, 2013 5:15pm EST

* Reuters is not responsible for the content in this press release.

  SAN DIEGO, CA, Feb 25 (Marketwire) -- 
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic
testing solutions, today announced that it will host its 2013 Quidel
Analyst and Investor Day at the Boston Marriott Long Wharf hotel in
Boston, Massachusetts on Thursday, March 7, 2013. 

    Quidel's management presentation will begin at 9:30 a.m. Eastern Time
with a question and answer session scheduled immediately following the
management presentation. During the presentation, the Company will
discuss business and financial developments and trends. The Company's
statements may contain or constitute material information that has not
been previously disclosed. For further details about the event, please
contact Ruben Argueta at rargueta@quidel.com.

    A live webcast and audio archive of the presentation will be available
via the Investor Relations section of the company's Web site at
www.quidel.com. Participants should allow approximately five to ten
minutes prior to the presentation's start time to visit the site and
download any streaming media software needed to listen to the Internet
webcast. A replay of the webcast will also be available on the company's
Web site for 14 days. 

    About Quidel Corporation

    Quidel Corporation serves to enhance the health and well being of people
around the globe through the development of diagnostic solutions that can
lead to improved patient outcomes and provide economic benefits to the
healthcare system. Marketed under the QuickVue(R), D3(R) Direct Detection
and Thyretain(R) leading brand names, as well as under the new Sofia(R)
and AmpliVue(R) brands, Quidel's products aid in the detection and
diagnosis of many critical diseases and conditions, including, among
others, influenza, respiratory syncytial virus, Strep A, herpes,
pregnancy, thyroid disease and fecal occult blood. Quidel's research and
development engine is also developing a continuum of diagnostic solutions
from advanced lateral-flow and direct fluorescent antibody to molecular
diagnostic tests to further improve the quality of healthcare in
physicians' offices and hospital and reference laboratories. For more
information about Quidel's comprehensive product portfolio, visit
www.quidel.com and Diagnostic Hybrids at www.dhiusa.com. 


Quidel Contact: 
Quidel Corporation 
Randy Steward 
Chief Financial Officer 
(858) 552-7931 

Media and Investors Contact:
Quidel Corporation
Ruben Argueta
(858) 646-8023

Copyright 2013, Marketwire, All rights reserved.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.